Study of a new treatment for childhood brain and CNS cancers
Part of Cancer clinical trials.
This trial tests a radioactive drug (177Lu-DTPA-Omburtamab) given directly into the fluid around the brain for children and teens with certain brain cancers or cancers that have spread to the central nervous system. It aims to see if this treatment is safe and effective for tumors that have come back or not responded to other therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 22 years old.
- Your tumor must be a type known to have a protein called B7-H3, such as neuroblastoma, medulloblastoma, or certain other brain cancers.
- Your cancer has come back or not responded to standard treatments and has spread to the brain or spinal cord lining.
- You need to have a device placed (like a shunt or Ommaya reservoir) to give the drug into the fluid around your brain, or be willing to have one placed.
- Your kidney and liver function must be good enough, and you must have recovered from side effects of previous treatments.
- You must not be pregnant and must use contraception if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if Lutathera, a radioactive drug that targets certain tumors, can help children and young adults with high-grade brain tumors or meningiomas that have come back or are growing. It aims to see if the treatment is safe and works.
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
This early-stage trial tests a new radioactive drug called [177Lu]Lu-XT771 injected directly into the brain cavity after glioblastoma surgery. It measures whether the drug is safe and helps slow tumor regrowth in patients whose cancer has come back after earlier treatments.
This Phase 2 trial tests a targeted radioactive medicine called 177Lutetium-DOTATATE in children with high-risk neuroblastoma that has returned or did not respond to treatment. It’s designed for tumors that show strong uptake on special scans, which may help the medicine find and treat cancer cells.
This trial tests a combination of chemotherapy drugs (topotecan given into the spine plus maintenance chemo) for children under 6 with high-risk embryonal brain tumors. The goal is to see if this approach can improve outcomes after initial treatment.
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Hear when a new Refractory Medulloblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.